• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eli Lilly increases access to clinical trials data for qualified researchers

Eli Lilly increases access to clinical trials data for qualified researchers

June 2, 2014
CenterWatch Staff

Eli Lilly will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This web site, which houses data from several trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and transparency of clinical trial results with researchers around the world.

Tim Garnett, M.D., senior vice president and chief medical officer, Eli Lilly, said, "By joining others in our industry to share clinical trial data with qualified researchers, we can quicken the pace of scientific advances needed to make life better."

The new portal differs from previous Lilly data-sharing sites in that access will be granted only after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent panel.

The multi-sponsor portal will include Lilly-sponsored interventional clinical studies from approved medicines and indications in the U.S. and E.U. in the following categories:

  • phase II, III or IV studies used as part of a regulatory approval submitted to the FDA on or after 1999;
  • phase II, III or IV global studies with a first patient visit after Jan. 1, 2007; and
  • phase II, III or IV global or regional/local studies in indications approved in both the U.S. and E.U. with a first patient visit after Jan. 1, 2014.

All shared data on the web site are anonymized to safeguard patients' privacy.

As part of Lilly's commitment to open access and transparency, the company established a web site in January to facilitate researchers' requests for data from interventional clinical trials for approved medicines and indications. However, this web site was an interim solution as Lilly worked with others in the pharmaceutical industry to create coordinated access to data from multiple study sponsors. Now that this coordinated access is available, Lilly will replace the current web site with the newly announced site.

Lilly also provides information on and links to information about our clinical studies on www.lillytrials.com. The web site includes results of all Lilly-sponsored phase II, phase III and phase IV clinical trials, as well as observational trials of Lilly-marketed products conducted anywhere in the world that were initiated on or after Oct. 15, 2002.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing